Skip to main content

Table 2 Comparison of demographic and clinical characteristics between low and high skeletal muscle index groups

From: Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies

Variables Low SMI (No. = 31) High SMI (No. = 71) P value
Observation period, days, median [range] 740 [161–3278] 706 [153–2902] 0.708
Age, years, median [range] 74 [53–89] 66 [34–86] 0.001
Sex (men/women), n 14/17 56/15 0.001
BMI in men, kg/m2, median [range] 21.0 [16.2–25.8] 24.4 [19.7–33.8] <  0.001
BMI in women, kg/m2, median [range] 22.0 [16.0–37.5] 23.9 [20.7–34.7] 0.009
Baseline L3 SMI in men, cm2/m2, median [range] 36.8 [31.5–40.7] 48.2 [42.2–64.4] <  0.001
Baseline L3 SMI in women, cm2/m2, median [range] 34.4 [25.6–36.5] 41.7 [38.1–55.6] <  0.001
Etiology (HBV/HCV/NBNC), n 1/23/7 10/27/34 0.003
ALT, U/L, median [range] 38 [13–123] 37 [9–243] 0.945
Total bilirubin, mg/dL, median [range] 0.8 [0.5–2.7] 1.0 [0.4–3.5] 0.107
Albumin, g/dL, median [range] 3.6 [2.1–4.7] 3.7 [2.0–4.9] 0.249
Platelet count, × 104/μL, median [range] 11.6 [3.2–61.5] 12.1 [2.2–80.9] 0.636
Child-Pugh classification (A/B), n 20/11 48/23 0.821
AFP, ng/mL, median [range] 19.5 [2.1–633,900] 24.7 [1.0–285,973] 0.881
TNM stage (I + II/III + IV), n 9/22 24/47 0.818
Maximum tumor diameter, mm, median [range] 26 [13–150] 36 [9–198] 0.662
Number of tumors (solitary/multiple), n 9/22 20/51 1.000
Treatment sessions between CT exams (1/≥2, sessions), n 17/14 42/29 0.828
mRECIST assessment (non-PD/PD), n 16/15 37/34 1.000
BCAA supplementation (presence/absence), n 22/9 50/21 1.000
  1. BMI body mass index, L3 SMI skeletal muscle index at third lumber vertebral level, HBV hepatitis B virus, HCV hepatitis C virus, NBNC non-B non-C, ALT alanine aminotransferase, AFP alpha-fetoprotein, CT computed tomography, mRECIST Modified Response Evaluation Criteria in Solid Tumors, PD progressive disease, BCAA branched-chain amino acid